Endometrial cancer metastatic – Diagnostics – Overview of Information and Clinical Research

Detecting metastatic endometrial cancer early can make a significant difference in treatment options and outcomes. Understanding when to seek testing, what diagnostic methods are used, and how doctors determine the best treatment path is crucial for anyone facing this diagnosis.

Introduction: Who Should Undergo Diagnostics

If you experience abnormal vaginal bleeding, it’s important to see a doctor right away. This is especially true if you notice bleeding between periods or any bleeding after menopause, which means going a full year without a period. Even light spotting after menopause should be checked by a healthcare professional, as it is the most common early warning sign of endometrial cancer at any stage.^[1]

Your regular doctor or obstetrician/gynecologist (OB/GYN) may be the first to suspect cancer based on your symptoms. However, a gynecologic oncologist should confirm the diagnosis and create your treatment plan. These are specialists who focus specifically on cancers of the female reproductive system and are up to date on the latest treatment options available.^[1]

Other symptoms that may indicate the need for diagnostic testing include unusual discharge from the vagina, pain in the pelvic area, feeling a mass or lump in the pelvic region, and unexplained weight loss. If the cancer has already spread to other parts of the body, you might experience additional symptoms related to the affected organ. For example, shortness of breath may suggest the cancer has reached the lungs, while swelling in the abdomen or yellowing of the skin and eyes could point to liver involvement.^[2]

⚠️ Important

Seeking expert care from the beginning matters greatly. As specialists emphasize, there’s no replacement for expertise in getting the diagnosis right the first time. It’s hard to go back and redo things once treatment has started, so patients should seek out the highest level of care available to them from the outset.

Around 10 to 15 percent of people with endometrial cancer are diagnosed after the disease has already spread to distant body parts. While metastatic endometrial cancer is not considered curable, newer treatments can slow the cancer’s growth, ease symptoms, and help patients live longer.^[1]

Classic Diagnostic Methods

When endometrial cancer is suspected, doctors use several diagnostic approaches to confirm the presence of cancer, determine how far it has spread, and distinguish it from other conditions. The diagnostic process typically begins with a physical examination and then moves to more specific tests.

Physical Examination

A pelvic exam is often the first step in diagnosing endometrial cancer. During this examination, a healthcare professional carefully inspects the outer genitals. Two fingers of one hand are inserted into the vagina while the other hand presses on the abdomen to feel the uterus and ovaries. A device called a speculum is inserted into the vagina to open the vaginal canal, allowing the doctor to look for visible signs of cancer or other problems.^[9]

A digital rectal exam may also be performed to check for abnormalities that could indicate the cancer has spread to nearby structures like the rectum.^[4]

Imaging Tests

Imaging tests create pictures of the inside of the body, helping doctors see the location and size of the cancer. One common imaging test is transvaginal ultrasound. In this procedure, a wandlike device called a transducer is inserted into the vagina while you lie on your back on an exam table. The transducer emits sound waves that generate images of your pelvic organs, including the uterus and surrounding tissues.^[9]

Other imaging methods include computed tomography (CT) scans, which use X-rays to create detailed cross-sectional images of the body. CT scans can help determine if cancer has spread to lymph nodes or distant organs like the lungs or liver. Magnetic resonance imaging (MRI) uses magnets and radio waves to create detailed pictures of soft tissues and can be particularly useful for assessing the extent of cancer within the uterus and nearby structures.^[5]

Positron emission tomography (PET) scans may be used to look for cancer throughout the body. This test involves injecting a small amount of radioactive sugar into the bloodstream. Cancer cells absorb more of this sugar than normal cells, making them show up brighter on the scan. Chest X-rays are often used to check whether cancer has spread to the lungs, which is one of the most common distant sites for metastatic endometrial cancer.^[5]

Tissue Sampling and Biopsy

To confirm a diagnosis of endometrial cancer, doctors need to examine tissue from the uterine lining under a microscope. An endometrial biopsy is a procedure where a thin tube is inserted through the cervix into the uterus, and a small sample of the endometrial lining is removed. This can often be done in a doctor’s office without anesthesia, though it may cause some cramping.^[5]

Another method is dilation and curettage (D&C), which involves widening the cervix and using a special instrument to scrape tissue from the inside of the uterus. This is typically done under anesthesia in an operating room or procedure room.^[5]

Hysteroscopy is a procedure that allows doctors to look directly inside the uterus. A thin, lighted instrument called a hysteroscope is inserted through the vagina and cervix into the uterus. This provides a clear view of the endometrium and allows doctors to take tissue samples from any suspicious areas. Hysteroscopy can be done at the same time as D&C.^[9]

Lymph Node Evaluation

Checking whether cancer has spread to lymph nodes is an important part of staging endometrial cancer. Lymph node dissection involves surgically removing lymph nodes from the pelvis and sometimes from the area around the aorta (the main blood vessel in the abdomen) to examine them for cancer cells. This is usually done during surgery to remove the uterus.^[5]

Laboratory Tests

Blood tests are part of the diagnostic workup. Although there is no specific blood test that can diagnose endometrial cancer, doctors may check levels of CA 125, a protein that can be elevated in some people with endometrial cancer, especially if the disease has spread beyond the uterus. Blood tests also help assess overall health and organ function before treatment begins.^[3]

In some cases, additional specialized tests may be ordered. These can include tests to look for genetic mutations or molecular markers that might influence treatment decisions. For instance, checking for microsatellite instability or specific gene mutations can help identify patients who might benefit from certain targeted therapies.^[3]

Staging After Diagnosis

Once endometrial cancer is confirmed, doctors assign it a stage from I to IV based on how far it has spread. Stage I means the cancer is found only in the uterus. Stage II indicates the tumor has spread to the cervix. Stage III means the cancer has spread beyond the uterus but is still in the pelvic area, potentially involving the vagina, ovaries, or lymph nodes. Stage IV means the cancer has spread to the bladder, rectum, or distant organs such as the lungs, liver, or bones.^[5]

In many cases, the exact stage cannot be determined until after surgery to remove the uterus and surrounding tissues. The removed tissue is examined by a pathologist who looks at the cancer cells under a microscope to determine the type of cancer, how aggressive it appears, and how deeply it has invaded the uterine wall.^[5]

⚠️ Important

Getting a second opinion after an initial diagnosis can be valuable. A second opinion can help confirm your diagnosis, provide a different perspective, and determine if there are other treatment options available. Most doctors welcome second opinions because they can provide confirmation or additional information. Don’t feel uncomfortable about seeking one—it’s a normal and accepted part of cancer care.

Diagnostics for Clinical Trial Qualification

When patients with metastatic endometrial cancer are being considered for enrollment in clinical trials, additional diagnostic tests and procedures may be required beyond standard diagnostic methods. Clinical trials have specific eligibility criteria that must be met, and certain tests help determine whether a patient qualifies.

Comprehensive Staging and Imaging

Clinical trials often require detailed documentation of where the cancer has spread. This typically involves a complete set of imaging studies, including CT scans of the chest, abdomen, and pelvis to identify all sites of metastatic disease. PET scans may also be required to provide a baseline measurement of tumor activity throughout the body. These baseline images allow researchers to track how well the treatment being tested works over time.^[10]

Tissue Analysis and Molecular Testing

Many modern clinical trials require specific molecular or genetic characteristics in the tumor. This means patients may need to provide fresh tissue samples or allow testing of previously collected tissue. Biomarker testing looks for specific proteins, genes, or other molecular features in cancer cells that might predict whether a particular treatment will be effective. For example, some trials enroll only patients whose tumors have certain genetic mutations or protein expressions.^[10]

Testing for microsatellite instability (MSI) or mismatch repair deficiency (dMMR) is increasingly important for clinical trial eligibility. These tests can identify tumors that might respond well to immunotherapy drugs. Testing for specific gene mutations in the tumor can also determine eligibility for trials of targeted therapies designed to block those particular mutations.^[3]

Performance Status Assessment

Clinical trials typically require patients to have a certain level of physical function, measured by what’s called a performance status. Doctors assess this using standardized scales that evaluate how well you can perform daily activities and how much the cancer is affecting your ability to care for yourself. This helps ensure that patients enrolled in trials are healthy enough to tolerate the experimental treatment.^[10]

Laboratory Testing

Comprehensive blood tests are required for most clinical trials. These include complete blood counts to check levels of red blood cells, white blood cells, and platelets. Tests of kidney and liver function are also standard, as these organs must be working well enough to process the drugs being tested. Blood tests may also measure tumor markers like CA 125 to establish a baseline for comparison during treatment.^[5]

Documentation of Prior Treatments

For patients with metastatic endometrial cancer considering clinical trials, detailed records of all previous treatments are essential. This includes documentation of surgeries performed, chemotherapy regimens received, radiation therapy administered, and responses to those treatments. Some trials are specifically designed for patients who have already received certain treatments, while others are only for patients who haven’t yet had any treatment for metastatic disease.^[10]

Confirmation by Expert Pathology Review

Many clinical trials require that the cancer diagnosis be confirmed by an expert pathologist at the institution conducting the trial. This means tissue samples from your biopsy may be sent to the trial center for review to ensure that the diagnosis meets the trial’s specific criteria. Different subtypes of endometrial cancer behave differently, and some trials enroll only patients with specific histologic types.^[10]

Prognosis and Survival Rate

Prognosis

The outlook for patients with metastatic endometrial cancer depends on several important factors. The most significant factor is the stage of the disease when it’s diagnosed. Around 10 to 15 percent of people with endometrial cancer are diagnosed after the disease has already spread to distant parts of the body. While metastatic endometrial cancer is not considered curable, newer treatments can slow the cancer’s growth, ease symptoms, and help patients live longer.^[1]

The type of cancer cells also affects prognosis. More aggressive types of endometrial cancer, such as serous adenocarcinomas and clear cell adenocarcinomas, are more likely to spread through the bloodstream to distant organs. The location where the cancer has spread matters as well. Cancer in the lungs is the most common site of distant spread, occurring in about 29.4 percent of cases with metastatic disease. The liver is affected in 14.9 percent of cases, bones in 10.5 percent, and the brain in 3.1 percent of cases.^[1]^[2]

Other factors that influence prognosis include the grade of the tumor (how abnormal the cancer cells look under a microscope), whether hormone receptors are present, the patient’s overall health and age, and how well the cancer responds to treatment. Patients with pathological features predictive of a high rate of relapse and those with cancer spread beyond the uterus at diagnosis have a higher rate of relapse despite receiving additional treatment.^[12]

It’s important to note that the most common cause of death in patients with endometrial cancer overall is actually cardiovascular disease, due to related metabolic risk factors that many endometrial cancer patients share, such as obesity and diabetes. This highlights the importance of managing overall health, not just the cancer itself.^[12]

Survival Rate

When endometrial cancer is found early and is limited to the uterus, the survival rates are very good. Most women with early-stage disease are cured with surgery alone. However, survival rates decrease significantly when the cancer has spread to distant organs. The specific survival rates for metastatic endometrial cancer depend on multiple factors including the exact stage, the cancer subtype, where it has spread, and the patient’s response to treatment.^[12]

Women with advanced-stage disease may benefit from chemotherapy, which has been shown to provide a survival benefit. Studies have demonstrated that patients with metastatic endometrial cancer can experience prolonged survival with appropriate treatment, though individual outcomes vary considerably. The availability of newer treatment options, including targeted therapies and immunotherapies for patients whose tumors have specific molecular features, has improved outcomes for some patients with metastatic disease.^[10]^[19]

While several treatment options are now available to treat women who present with metastatic endometrial cancer, the overall prognosis remains challenging. Treatment goals often focus on slowing disease progression, managing symptoms, and maintaining quality of life for as long as possible. Each patient’s situation is unique, and survival times can vary widely based on individual circumstances. Discussing your specific prognosis with your gynecologic oncologist can provide more personalized information based on your particular situation.^[5]

#1 Clinical Trials Search in Europe